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Background: As its name indicates, anti-Müllerian hormone (AMH) is primarily found
as an inhibitor of the Müllerian duct in male fetus. On the other hand, AMH may act
as a mediator of Müllerian duct-derived female tissue, such as endometrium in normal
and pathological conditions. However, the role of AMH in the functional regulations of
endometriosis is not well understood. It can be hypothesized that AMH in peritoneal
fluids may affect the activity of peritoneal endometriosis. In this study, we investigated
the levels of AMH in peritoneal fluids (PF) in women with and without endometriosis.
Methods: PF were collected during laparoscopy from 90 women diagnosed as having
advanced endometriosis (rASRM stage III, n = 30; stage IV, n = 60), and 32 women
without endometriosis were served as control. Paired serum samples were also collected
before the surgery. AMH in PF and serum were measured by ELISA. Individual clinical
information was collected. AMH levels were compared according to the presence of
endometriosis. The expression of AMHR2 in peritoneal endometriotic lesions obtained
during laparoscopy was examined by immunohistochemistry.
Results: AMH levels in PF were positively and significantly correlated with serum
AMH levels in both women with and without endometriosis (R2 = 0.17, P <
0.0001; R2 = 0.30, P = 0.001, respectively). Serum AMH levels were inversely
and significantly correlated with age in women with endometriosis (R2 = 0.092,
P = 0.004) and in control women without statistical significance (R2 = 0.078, P =
0.12). AMH levels in PF were also inversely but not significantly correlated with age
in women with and without endometriosis (R2 = 0.029, P = 0.11 and R2 = 0.027,
P = 0.37, respectively). Mean age and serum AMH levels were not significantly different
between two groups. On the other hand, AMH levels in PF were significantly lower
in women with endometriosis compared to those of control women [2.15 ± 2.13
(mean ± SD) vs. 4.40 ± 4.77 ng/mL, P = 0.0001]. AMHR2 are localized at glandular
epithelium and stromal cells in the ectopic endometrium of peritoneal endometriosis.
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Conclusions: Women with endometriosis may present lower PF AMH levels even if
they retain serum levels similar to women without disease. As peritoneal endometriosis
expresses a specific receptor for AMH, lower AMH levels in PF of women with advanced
endometriosis may be involved in the pathophysiology of peritoneal endometriosis.
Keywords: AMH (anti-Müllerian hormone), peritoneal fluid, endometriosis, AMH receptor type2 (AMHR2),
peritoneal lesions
INTRODUCTION
Endometriosis is an estrogen-dependent chronic inflammatory
disease. It may affect 5–10% of women of reproductive age (1).
The disease is manifested by varieties of pain symptom, such
as dysmenorrhea, dyschesia, dyspareunia, and chronic pelvic
pain. It is also found in up to 50% of women with infertility
(2). Retrograde menstrual flow via fallopian tubes is believed to
play main roles in the development of peritoneal endometriosis,
though the pathogenesis of the disease remains controversial.
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein
which belongs to the transforming growth factor-β superfamily.
AMH was primarily found as a substance involved in the
regression of the Müllerian duct in the male fetus produced from
Sertoli cells (3). In female, the granulosa cells of early growing
ovarian follicles are the sole source of serum AMH levels, which
declines with age. Serum AMH levels are utilized as a marker of
ovarian reserve in clinical infertility care (4).
On the other hand, AMH may act as a functional mediator
of female reproductive tissue derived from the Müllerian
duct, such as the ovarian epithelium, pelvic peritoneum, and
endometrium. There have been several reports describing the
potential inhibitory role of AMH on normal and pathological
conditions of the uterus and ovary including cancer (5, 6). It
may exert its effect via a specific receptor designated as AMH
receptor (AMHR) type I and II, where the type II receptor
(AMHR2) exerts its function in specific binding to AMH (7). The
expression of AMHR2 in human tissue includingMüllerian duct-
derived female reproductive organs, such as endometrium, had
been reported (8). However, the role of AMH in the functional
regulations of human endometrium is not well understood.
Peritoneal fluids (PF) in women with endometriosis may
contain a series of inflammatory cytokines and chemokines,
which are involved in the growth and progression of
endometriotic lesions (9). These macromolecules are derived
from ectopic endometrial glandular cells, stromal cells,
surrounding vascular cells, and infiltrated macrophages. At
the same time, inhibitors against these stimulants may also be
produced. Peritoneal fluids may work as a reservoir of growth
mediators of endometriotic lesions. Thus, the balance between
stimulants and inhibitors in PF may affect the growth abilities of
endometriotic lesions.
Therefore, it can be hypothesized that different levels of
AMH in PF may affect the growth and progression of peritoneal
endometriosis. In this study, we investigated the levels of
AMH in PF in women with and without endometriosis and
compared them according to the age of the subjects and
the presence of disease. We also studied the expression of a
specific receptor of AMH (AMH receptor type 2, AMHR2) in
peritoneal endometriosis. The aim of this study is to delineate
the possible involvement of AMH in the pathogenesis of
peritoneal endometriosis.
MATERIALS AND METHODS
We performed a retrospective analysis using archivally stored
paired samples of serum and PF from women diagnosed
as having advanced endometriosis and women without
endometriosis, which were collected during laparoscopic surgery
from 2012 to 2018.Written consent for the usage of these samples
for the research purpose was obtained, and the institutional
review board approved this study. In women with endometriosis,
the severity of the disease was classified according to the rASRM
scoring system at the time of laparoscopy. Endometriotic lesions
were excised and coagulated by bipolar energy devices. Control
women had laparoscopy for benign gynecological conditions,
such as benign ovarian tumor, uterine fibroids, uterine anomaly,
and unexplained infertility.
PF were collected at the beginning of the surgery and
centrifuged at 3,000 g for 10min, then the supernatant was stored
at −80◦C until the examinations. AMH in PF were measured by
ELISA (AMH Gen II ELISA, Beckman Coulter). Blood samples
were collected before the surgery and were centrifuged and sera
were stored at −80◦C, and serum AMH levels were measured
in a similar way to PF samples. Individual clinical backgrounds,
operative findings, and pathological diagnosis after the surgeries
were collected from patients’ records. To eliminate the effects of
subjects with abnormally higher AMH production, women with
solid ovarian tumor or irregular menstruation with serum AMH
levels higher than 10.0 ng/mL were excluded from the present
study. The differences between AMH in PF and serum AMH in
individual subjects were calculated by subtraction (AMH in PF
minus serum AMH).
Peritoneal endometriotic lesions were obtained during
laparoscopy. The tissues were fixed in 10% formalin and
embedded in paraffin, and 5-µm thick sections were made.
Hematoxylin and eosin (H.E.) staining sections were made for
routine pathological diagnosis. The tissue samples with intact
endometrial glandular epithelial cells and stromal cells were
selected for the examination of the expression of AMHR2 by
immunohistochemistry as previously described (10). Briefly, 5-
µm sections were pretreated in 0.05% citraconic anhydride
solution (Immunosaver, Nissin EM) for antigen retrieval.
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TABLE 1 | Clinical backgrounds and AMH levels in serum and peritoneal fluids.
Endometriosis Control
Stage* of endometriosis III IV
Number of subjects 30 60 32
Mean age, years old (range) 32.4 ± 4.7 32.0 ± 6.9
(15–44)
31.0 ± 4.4 (24–41) 33.1 ± 4.7 (21–45)
Subjects >35 years old 7 (23%) 23 (38%) 12 (38%)
Subjects with infertility 12 (40%) 42 (70%)
†
14 (44%)
Subjects with endometriomas 26 (87%) 58 (97%) NA
Mean lesion score by rASRM system (range) 21.6 ± 6.5 (6–38) 33.4 ± 11.0 (6–58) NA
Mean adhesion score by rASRM system (range) 8.3 ± 6.0 (0–28) 44.7 ± 26.5 (6–96) NA
Mean serum AMH levels, ng/mL (range) 2.90 ± 2.21 3.17 ± 2.93
(0.02–9.82)
3.57 ± 2.40 (0.19–9.79) 2.57 ± 2.05 (0.1–9.91)
Mean PF AMH levels, ng/mL(range) 2.15 ± 2.13‡ 4.40 ± 4.77‡
(0.01–18.2)
2.11 ± 1.47 (0.01–5.56) 2.17 ± 2.41 (0.01–11.4)
Values are expressed as mean ± SD (standard deviation); NA, not applicable; PF, peritoneal fluids.
*Stage of endometriosis were classified according to the revised ASRM (American Society of Reproductive Medicine) scoring system.
†
P = 0.006 vs. stage III, P = 0.01 vs. control, kai square test.
‡P = 0.0002, student-t test.
FIGURE 1 | The graph shows linear correlation between serum AMH levels and AMH levels in peritoneal fluids (PF) in women with endometriosis (red dot) and without
endometriosis (blue dot).
After blocking endogenous peroxidase activity and nonspecific
binding, they were incubated with rabbit polyclonal anti-AMHR2
antibody [AMHR2 (N-term), Rabbit poly ABG-AP7111a, Life
Span Biosciences] overnight. After washing the sections, they
were incubated with peroxidase-labeled polymer conjugated
to goat anti-rabbit immunoglobulins (EnVision; DAKO) and
washed as previously described. Specific immunoreactivity was
visualized by 3,3′-diaminobenzidine tetrahydrochloride. The
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FIGURE 2 | (A) The graph shows linear inverse correlation between serum AMH levels and age in women with endometriosis (red dot) and control women without
disease (blue dot). (B) The graph shows linear inverse correlation between AMH levels in peritoneal fluids and age in women with endometriosis (red dot) and control
women without disease (blue dot).
FIGURE 3 | (A) The comparison of serum AMH levels between women with endometriosis and control women without disease. (B) The comparison of AMH levels in
peritoneal fluids between women with endometriosis and control women without disease. *AMH levels in PF were significantly lower in women with endometriosis
compared to those of control women without disease. Boxes represent the distance (interquartile range) between the first (25%) and third (75%) quartiles, and
horizontal lines in the boxes represent median values. Blue horizontal line represents mean value and blue-colored square box represents 95% confidence interval.
Each dot represents the exact value of individual cases.
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FIGURE 4 | The comparison of the individual difference between AMH in peritoneal fluids and serum AMH calculated by subtraction. *The differences were
significantly lower in women with endometriosis compared to those of control women without disease. Boxes represent the distance (interquartile range) between the
first (25%) and third (75%) quartiles, and horizontal lines in the boxes represent median values. Blue horizontal line represents mean value, and blue-colored square
box represents 95% confidence interval. Each dot represents exact value of individual case.
sections were counterstained with Mayer’s hematoxylin. For
negative controls, sections were incubated with rabbit IgG
instead of specific antibodies at the same dilution. Positive
controls consisted of a full-thickness human endometrium
derived from a hysterectomized uterus were used.
For statistical analysis, continuous variables are compared
with unpaired student-t test and Mann–Whitney U test.
Categorical variables are compared with kai square test and
Fisher’s exact test. Linear regression analyses were performed to
detect a significant correlation between two continuous variables.
All statistical analyses were performed with computer software
(JMP Pro 14.0.0, SAS institute Japan, Tokyo). P values under 0.05
were considered as statistical significance.
RESULTS
Paired serum and PF AMH levels were examined in 90 women
with advanced endometriosis (rASRM stage III, n = 30; stage IV,
n = 60) and 32 control women. Indications of surgery in control
women were benign ovarian tumor (n = 15), uterine fibroids
(n = 9), and diagnostic laparoscopy for uterine anomaly or
infertility (n = 8). The clinical backgrounds of study subjects are
summarized in Table 1. We did not find a statistically significant
difference in the distributions of age between two groups. The
proportions of women with infertility were significantly higher
in women with stage IV (n = 42, 70%) compared to those of
women with stage III and control (n= 12, 40%, p= 0.006, and n
= 14, 44%, P= 0.01, respectively). In women with endometriosis,
various sizes of endometriomas were found in 84 women [26
(87%) in stage III and 58 (97%) in stage IV].
Significant linear correlations were found between the paired
samples (serum AMH and AMH in PF) in women both with
and without endometriosis (R2 = 0.17, P < 0.0001; R2 = 0.30,
P = 0.001, respectively, Figure 1). Serum AMH levels were
inversely and significantly correlated with age in women with
endometriosis (R2 = 0.092, P = 0.004) and in control women
without statistical significance (R2 = 0.078, P = 0.12). AMH
levels in PF were also inversely but not significantly correlated
with age in women with and without endometriosis (R2 = 0.029,
P = 0.11 and R2 = 0.027, P = 0.37, respectively, Figure 2).
We did not find a significant difference in serum AMH levels
according to the presence of endometriosis [endometriosis 2.90
± 2.21 (mean ± SD) ng/mL vs. control 3.17 ± 2.93 ng/mL, P =
0.29 (Figure 3A)]; however, AMH levels in PF were significantly
lower in womenwith endometriosis compared to those of control
women [endometriosis 2.08± 2.06 (mean± SD) vs. control 4.40
± 4.77 ng/mL, P = 0.0002 (Figure 3B)]. Individual differences
between AMH in PF and serum AMHwere significantly lower in
women with endometriosis [endometriosis −0.75 ± 2.35 (mean
± SD) vs. control 1.23± 4.01, P = 0.001 (Figure 4)].
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FIGURE 5 | The photomicrograph of immunohistochemistry for AMHR2 and hematoxylin and eosin (H.E.) staining in ectopic and eutopic endometria.
Immunolocalization of AMHR2 in human peritoneal endometriosis (A,C) and corresponding H.E. staining in adjacent sections (B,D). Brown-colored positive
immunoreactivity was found in glandular epithelium and also in endometrial stroma of peritoneal lesions (A,C). We found AMHR2-positive immunoreactivity in human
eutopic endometrium derived from full-thickness sampling of endometrium (positive control, E,F). Positive immunoreactivity was found in glandular epithelium of
basalis endometrium (E) and in glandular epithelium and stroma of superficial functional part of eutopic endometrium (F). All bars indicate 100µm.
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We found AMHR2 expression in peritoneal endometriotic
lesions. The expressions were positive in glandular epithelium
and stromal cells (Figures 5A–D). In the eutopic endometrium
(positive control), AMHR2 are mainly localized at glandular cells
and staining was more intense in the basal layer than in the
functional layer (Figure 5E). AMHR2 is also strongly expressed
at superficial glands and stromal cells (Figure 5F). We did not
detect an immunoreaction in ectopic and eutopic endometria in
negative control which replaced the primary antibody to AMHR2
to rabbit IgG (data not shown).
DISCUSSION
Serum AMH levels are utilized as a marker of ovarian response
in the field of clinical reproductive medicine (4). On the other
hand, AMH, also designated as Müllerian inhibitory substance
(MIS), is originally discovered as a key molecule involved in the
regression of the Müllerian duct in male fetus (3). The Müllerian
duct is an embryonic precursor tissue (anlagen) of the uterus,
fallopian tubes, and pelvic peritoneum. AMH may work as an
inhibitor to the tissue derived from the Müllerian duct. In the
study of endometrial and epithelial ovarian cancer cell lines,
both may be Müllerian duct derivatives; AMH showed growth
inhibitory effects on these cells (6). In addition, eutopic and
ectopic endometria treated with AMH in vitro may decline their
proliferative activity and may increase the intracellular signal
of apoptosis (11–13). These previous reports may indicate that
the endometrium and endometriotic tissue may be the target
of AMH; however, the exact role of AMH in the growth and
maintenance of endometriosis is not fully elucidated. As we show
in this study, the presence of different levels of AMH in peritoneal
fluids may implicate the role of these molecules in the growth and
progression of peritoneal endometriosis.
Substances accumulated in peritoneal fluids may constitute
secretion and permeation from the peritoneum and surrounding
vascular flows. The concentrations of certain substances in
peritoneal fluids may be correlated with those of serum levels.
In women of reproductive age, the production from granulosa
cells of ovarian follicles is solely responsible for AMH in serum
because it becomes undetectable in the period of menopausal
transition or after bilateral oophorectomy (14). In this present
study, we found a significant correlation between serum AMH
and AMH in PF in both women with endometriosis and
control women without disease. AMH levels in PF and their
correlation with serum AMH levels in women with and without
endometriosis had been reported previously (15). Similar to our
study, this study also showed a significant linear correlation
between AMH in peritoneal fluids and in serum in both
women with endometriosis and control women without disease.
However, the severity of endometriosis was not considered
in the previous report. In addition, age distributions between
women with endometriosis and control women without disease
significantly differed. In this study, we found significant inverse
linear correlations between age and serum AMH and AMH in PF
in women with endometriosis. The trends of linear correlations
between age and AMH in PF in women with and without
endometriosis were also reported in the previous study (15),
which correspond with our present findings. AMH levels in PF
may correlate with age-dependent decline in ovarian reserve.
In this study, we did not find a significant difference in serum
AMH levels according to the presence of endometriosis. On the
other hand, when we compare AMH in PF according to the
presence of endometriosis, we found significantly lower AMH in
PF in women with advanced endometriosis compared to those
of control women. These results may indicate that AMH in PF
may be affected by the presence of endometriosis. Although the
cause of PF-specific alteration in AMH levels is unclear, lower
AMH in PF in women with endometriosis may be related to
pathophysiology of endometriosis. If AMH act as an inhibitor
to Müllerian duct-derived tissue, lower AMH levels in PF can
be interpreted as a putative growth promotive environment
for disease.
In this study, we confirmed localization of a specific receptor
for AMH (i.e., AMHR2) in peritoneal endometriosis. Previous
study also reported the expression of AMH and AMHR2 mRNA
and protein in endometrial glandular epithelium and stromal
cells in endometrial tissue obtained during infertility evaluation
(10). In another study, isolated endometrial stromal cells derived
from ovarian endometriosis also express AMHR2, and AMH
showed growth inhibition on these cells in vitro (11) In addition,
higher AMH and AMHR2 mRNA levels in eutopic and ectopic
endometria of women with endometriosis compared to those
of control women without disease had been reported (16).
These reports indicate that endometriotic lesion is also a target
of AMH, and the effects of AMH may be more pronounced
compared to those of the eutopic counterpart. Ovarian and
deep infiltrated endometriosis but not peritoneal endometriotic
foci were utilized in previous studies. Since these lesions may
have different pathological entities (17), peritoneal endometriosis
and AMH in PF may differently interact compared to other
types of endometriosis. Our present study may implicate that
AMH in peritoneal fluids may exert its effect via AMHR2 on
peritoneal endometriosis.
In conclusion, the concentration of AMH in PF correlates
with age and serum AMH levels, but these associations may
be less relevant in women with endometriosis. AMH levels in
peritoneal fluids may differ according to the presence of ovarian
endometriosis which lowers productions of AMH from ovarian
granulosa cells. Peritoneal endometriosis expresses AMHR2, the
specific receptor for AMH, which may implicate a functional role
of AMH in growth maintenance of these lesions.
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